Your session is about to expire
← Back to Search
MuST AKT Program for Kidney Transplant (MuST AKT Trial)
N/A
Waitlist Available
Led By Dr. Shojai
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from start date to end date of study recruitment, up to 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial will help researchers understand if the intervention they've developed is effective in helping people with kidney failure find living donors, which could potentially improve patient outcomes and reduce healthcare costs.
Who is the study for?
This trial is for English-speaking individuals with kidney failure who have completed a 'kidney transplant introduction' module and are eligible for a transplant. It's not open to those who already have a donor, have had previous transplants, need multiple organ transplants, or score low on certain psychosocial or literacy tests.
What is being tested?
The MuST AKT intervention is being tested to help patients find living kidney donors through their social networks. The goal is to increase the number of living donor kidney transplants in Alberta by providing personalized support from a multidisciplinary team.
What are the potential side effects?
Since this trial involves an educational and support intervention rather than medication, traditional side effects are not applicable. However, participants may experience emotional or psychological impacts as they engage with their social networks.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from start date to end date of study recruitment, up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from start date to end date of study recruitment, up to 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Living Kidney Donor Transplantation
Secondary study objectives
Contact Living Donor Services
Living Kidney Donor Evaluation Approved
Living Kidney Donor Evaluation Started
Other study objectives
Consent rate
Contact Living Donor Services (numbers)
Conversation started
+17 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
This arm will receive the MuST AKT intervention, which is a multidisciplinary, tailored person-centered behavioural intervention designed to "help and enable" the potential kidney transplant recipients to achieve what is required to receive a living donor kidney transplantation.
Group II: Usual Care (control)Active Control1 Intervention
In the usual care (control) condition, participants will go through the current standard of care, which is a social worker assessment.
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
942 Previous Clinical Trials
434,329 Total Patients Enrolled
Alberta Innovates Health SolutionsOTHER
53 Previous Clinical Trials
94,077 Total Patients Enrolled
Dr. ShojaiPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
38 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am eligible for a transplant involving multiple organs.I am eligible for a kidney transplant.
Research Study Groups:
This trial has the following groups:- Group 1: Intervention
- Group 2: Usual Care (control)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.